Canaccord Genuity Reiterates Buy Rating for Artivion, Inc. (AORT)
Canaccord Genuity maintains its buy rating with a $36 price target for Artivion, Inc, a 70.09% upside from the current price.
Key Points
- Canaccord Genuity reiterated its buy rating on Artivion, Inc. (NYSE:AORT) with a $36 price target on June 16, 2026.
- Canaccord Genuity's $36 price target implies 70.09% upside from Artivion, Inc.'s ($AORT) current $21.16 share price.
- Shares of Artivion traded near $21.09, with a market cap of $1.02 billion and a P/E ratio of 84.28.
- Other analysts also maintain a strong buy consensus with a target mean price of $42.0.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Canaccord Genuity has reiterated its buy rating on Artivion, Inc. (NYSE:AORT), setting a price target of $36. This update came from analyst William Plovanic on June 16, 2026. Artivion's shares were trading around $21.09 at the time of the report.
Other Institutional Activity in Artivion
BlackRock, Inc. increased its stake in Artivion by 106,735 shares, ending with a total of 6,474,854 shares valued at approximately $237.1 million. FMR LLC also raised its holdings by 41,560 shares, bringing its total to 2,583,427 shares worth about $94.6 million. On the other hand, Nomura Asset Management International Inc. reduced its position by 157,325 shares, leaving it with 2,456,146 shares valued at $89.9 million. Morgan Stanley added 12,552 shares, holding 2,269,294 shares valued at $83.1 million. State Street Corp increased its holdings by 97,353 shares, totaling 1,682,273 shares worth about $61.6 million.
Artivion, Inc. Stock Down 20.9%
Artivion, Inc. (NYSE:AORT) has a market capitalization of approximately $1.02 billion. The company's P/E ratio stands at 84.28, with a forward P/E of 28.47. Artivion's stock has a 52-week low of $19.16 and a high of $48.25. The 50-day moving average is $28.96, while the 200-day moving average is $38.68. The company has a beta of 1.258, indicating moderate volatility compared to the market. Artivion maintains a solid current ratio of 3.857 and a quick ratio of 1.741, with a debt-to-equity ratio of 57.309.
Recent Earnings
In its most recent earnings report, Artivion reported revenue of $458.7 million, reflecting a growth rate of 17.5%. The company achieved a net margin of 2.5% and a return on equity of 3.1%. Earnings per share were reported at $0.25. Artivion is expected to announce its next earnings on August 6, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target cuts vs 0 raises.
-
EPS & revenue
EPS missed estimates by 40.1%. Revenue missed estimates by 1.5%.
-
Profit surprise
EBITDA missed by 41 percent. Operating income missed by 11 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
2 target cuts.
-
Earnings quality
Gross margin down 2.7 points. Operating margin up 4.3 points. Negative free cash flow.
Earnings Call Summary
The company reported 116.3 million dollars in first quarter revenue, up 12 percent year over year, with adjusted EBITDA reaching 22.1 million dollars. On-X heart valve grew 17 percent and tissue processing grew 23 percent, but stent grafts grew only 10 percent due to lower AMDS starter set sales and weaker international markets. Management acquired Endospan to bring NEXUS aortic arch stent grafts to the U.S. market starting January 2027, completing a comprehensive aortic portfolio.
Guidance Artivion lowered full year 2026 guidance to 480 million to 496 million dollars, down from prior expectations. The company expects constant currency revenue growth of 7 percent to 11 percent for the year. AMDS starter set sales in the U.S. fell short in the first quarter, and international stent graft sales softened, particularly in the Middle East. Management expects AMDS PMA approval by mid-year and plans to launch NEXUS in January 2027.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Insider Buying and Selling at Artivion, Inc.
On June 11, 2026, Andrew Green, SVP of Regulatory and Quality, executed a planned sale of 44,001 shares at an average price of $20.70. Earlier on the same day, he bought 44,001 shares, although the price was not disclosed. Anthony Semedo engaged in several transactions, including buying 7,576 shares on May 18, 2026, and buying 6,325 shares on June 2, 2026, with the transaction details not fully disclosed.
Analysts Set New Price Targets
On June 16, 2026, Canaccord Genuity maintained its buy rating for Artivion with a $36 price target. Other analysts such as Citizens and Needham have also maintained buy ratings with higher targets of $48 and $44, respectively. The consensus among analysts remains strong buy with a mean target price of $42.0 based on eight opinions.
About Artivion, Inc.
Artivion, Inc. is a healthcare company based in Kennesaw, Georgia, specializing in medical devices and implantable human tissues. The company provides a wide range of products, including prosthetic heart valves, stent graft systems, and surgical sealants. Founded in 1984 and led by CEO James Patrick Mackin, Artivion markets its products primarily to hospitals and healthcare facilities worldwide through a direct sales team. The company employs around 1,800 people.
Bottom Line
Artivion, Inc. continues to attract attention from analysts and institutional investors, with Canaccord Genuity reiterating a buy rating and setting a $36 price target. The company's stock is trading below its 52-week high, offering potential upside as suggested by the analysts' targets. Investors should note that 13F filings and analyst ratings are backward-looking indicators and may not reflect current conditions.
Get Artivion, Inc. alerts
New 13F filings, insider trades, and analyst moves on $AORT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.